Shah Discusses Hope for CAR T-Cell Therapy in Multiple Myeloma
Nina Shah, MD, discusses the question of whether CAR T-cell therapy is ready for primetime in patients with multiple myeloma.
Nina Shah, MD, an associate professor of Medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the question of whether chimeric antigen receptor (CAR) T-cell therapy is ready for primetime in patients with multiple myeloma.
Shah says it is not primetime for CAR T cells in multiple myeloma yet, but the reason for asking this question is because of the significant responses that have been demonstrated with CAR T cells already in this space. The therapy induced response rates around 85% to 90% in patients who are heavily pretreated with multiple myeloma, where the median number of prior lines is 7. These kind of response rates are unheard of in this patient population, Shah says, and CAR T-cell therapy is ultimately rescuing a lot of really sick patients.
Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab
November 18th 2024During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.
Read More
